Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs
Jason Grebely(UNSW Sydney), Carla Treloar(UNSW Sydney), Behzad Hajarizadeh(UNSW Sydney), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Evan B. Cunningham(UNSW Sydney), Lise Lafferty(Sydney Hospital), Alison D. Marshall(Sydney Hospital), Javier Cepeda(Johns Hopkins University), Matthew Bonn, Alexandra B. Collins(Brown University), Jaimie P. Meyer, Andreea Adelina Artenie(At Bristol), Joshua A. Barocas(University of Colorado Denver), Jeffrey V. Lazarus(The Graduate Center, CUNY), Rachel Sutherland(UNSW Sydney)
Cited by 14
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694